MPI Research Implements Gyrolab xP

MPI Research has acquired and implemented a Gyrolab xP workstation from Gyros AB into its time-critical project workflows. Gyros provides microfluidic technologies to miniaturize and automate immunoassays.

Alan Breau, MPI’s vice president for Bioanalytical/Analytical Services said, “Data from immunoassays underpin many critical decisions within complex project workflows. Our goal as a CRO is to deliver high quality results as rapidly and cost-effectively as possible to our clients in the biopharmaceutical industry. The automated, precise nanoliter-scale immunoassay platform from Gyros enables us to quickly develop project specific biomarker, pharmacokinetic (PK) and immunogenicity assays and to easily transfer the running of established assays thereby freeing staff for other tasks. We believe that this investment will significantly impact the cost-efficiency as well as the turnaround time of our preclinical and clinical studies.”

Erik Walldén, chief executive officer at Gyros, said, “With major biopharmaceutical companies using our platform to increase workflow efficiency, it is extremely pleasing that a growing number of their service providers are following suit. We have seen several examples of highly successful collaborations where both parties have benefited from increased productivity overall and noted the ease with which assays can be transferred between sites. This purchase by a well-established company such as MPI Research reflects the growing acceptance of our nanoliter-scale immunoassay platform within the industry.”